With Mounting Evidence CV-19 Causes Severe Lung Damage, This Biotech Firm Could Play a Major Role in Its Treatment

U.S. FDA Says Citius Pharmaceuticals (STOCK:CTXR) Can Apply for Fast-Track Designation

News Update 10-7-20:
Citius Pharmaceuticals Signs an Exclusive Worldwide Licensing Agreement with Novellus Therapeutics for Unique iMSC-Therapy for Acute Inflammatory Respiratory Conditions including COVID-19 Related Acute Respiratory Distress Syndrome (ARDS)

The CV-19 pandemic is sparking a surge of acute respiratory distress syndrome (ARDS) in intensive care units all over the world.(1)

But there’s an even bigger problem.

There are no treatments(2), which opens the door to BIG opportunity for Citius Pharmaceuticals (STOCK:CTXR). According to Myron Holubiak, chief executive officer, Citius:(6)

“ARDS is the most common cause of respiratory failure and mortality in CV-19 patients. Currently, there is no proven treatment for ARDS. Literature supports the use of counter-inflammatory MSCs for ARDS, and papers published in China have shown that at least seven CV-19 patients with ARDS responded to MSC therapy. Clearly this is an avenue that shows promise and should be pursued as a potential treatment for ARDS.”(3)

According to the National Institutes of Health about 80% of COVID-19 infections are mild or asymptomatic and never require hospitalization but about 5% of patients become critically ill and develop acute respiratory distress syndrome.(4)

Johns Hopkins Medical added that CV-19 can cause lung complications such as pneumonia and, in the most severe cases, acute respiratory distress syndrome.(5)

This is where Citius Pharmaceuticals (STOCK:CTXR) Comes Into Play

Specialty pharmaceutical company, Citius Pharmaceuticals (STOCK:CTXR) signed an exclusive agreement to in-license a stem-cell therapy for acute respiratory distress syndrome or ARDS from a subsidiary of Novellus Inc.

Novellus’s patented process uses its exclusive non-immunogenic synthetic messenger ribonucleic acid or mRNA molecules to create induced pluripotent stem cells (iPSCs) that, in turn, generate mesenchymal stem cells or MSCs with superior immunomodulatory properties.

MSCs have been shown to be safe in over 900 clinical trials and to be safe and effective in treating a number of inflammatory diseases, including ARDS.

U.S. FDA Says it Can Apply for Fast-Track Designation

To date, the company has received a written response from the U.S. Food and Drug Administration (FDA) in regards to its pre-investigational new drug (PIND) application for its induced mesenchymal stem cells (iMSCs) to treat and reduce the severity of ARDS.(6)

The FDA acknowledged that the Company could apply for fast track designation and also provided Citius with the chemistry, manufacturing, and control (CMC) requirements for the proposed trials.

Better, the company plans to initiate actions on the FDA’s recommendations and follow up with the FDA with an Investigational New Drug (IND) application under the CV-19 Treatment Acceleration Program (CTAP).

Holubiak added, “No effective pharmacotherapy for ARDS exists, and ARDS-related morbidity and mortality are high. MSCs have been studied in the treatment of lung injury, and we aim to build upon this work with Novellus’s iPSC-derived MSCs to improve the immunomodulatory response in humans. We have assembled a team of experts who are dedicated to advancing this project to an Investigational New Drug (IND) application as quickly as possible.”(7)

Citius Pharmaceuticals (STOCK:CTXR) Created an ARDS Scientific Advisory Board

Citius Pharmaceuticals formed the Citius ARDS (Acute Respiratory Distress Syndrome) Scientific Advisory Board to provide the company expert guidance on  its planned development of induced mesenchymal stem cells (iMSCs) under option from Novellus, Inc. to treat and reduce the severity of acute respiratory distress syndrome (ARDS) associated with CV-19.(8)

The ARDS Advisory Board consultants include:

Citius Pharmaceuticals (STOCK:CTXR) Exposed to a $400 Million Opportunity

Outside of ARDS, the company just announced progress in the development of Mino-Wrap, which may be able to help reduce post-operative infections associated with surgical implants.

Mino-Wrap is a gel-containing a film that is used to wrap the tissue expander used in breast reconstructive surgeries.  In order to stimulate early consultation and potentially speed the development of Mino-Wrap, the company has submitted a briefing package to the FDA Division of Anti-Infective Products.

“The published rate of infection for tissue expanders used in breast reconstructive surgery is between 2.5 % and 24%, with an estimated mean at around 12% to 14%.  We believe Mino-Wrap has the potential to provide a significant reduction in the incidence of infection, sparing the patient the pain and discomfort of extended hospitalization and further aggressive and lengthy courses of antibiotics in an attempt to salvage the TEs. In many cases the TE is removed leading to a delay in lifesaving chemo-radiation therapy, which can be a devastating consequence for the patient,” added Holubiak.(9)

“We currently expect to have a PIND meeting with the FDA before the end of the year and begin a Phase 2 clinical study in 2021. The market opportunity for Mino-Wrap in preventing infections following breast implant surgeries following mastectomies is estimated to be $400 million,” added the company.

Citius Pharmaceuticals (STOCK:CTXR) Also Exposed to Explosive $1.84 Billion Opportunity

 The company’s Mino-Lok product is an antibiotic lock solution that used to treat patients with catheter-related bloodstream infections, or CRBSIs.

“CRBSIs are very serious, especially in cancer patients receiving therapy through central venous catheters (CVCs) and in hemodialysis patients where venous access presents a challenge,” says the company.(10)

In a Phase 2b trial, the Mino-Lok product appeared to have demonstrated a 100% efficacy rate in salvaging colonized CVCs; the Mino-Lok product is claimed to have had no significant adverse events compared to an 18% serious adverse event rate when infected CVCs were removed and replaced.

It’s now currently in a Phase 3 superiority trial.

If successful, this could expose CTXR to a massive $1.84 billion market by 2028. It was worth $1.24 billion in 2017, according to Delve Insight. In addition, the total incidence of CRBSI in the global market is as high as four million patients.(11)

Incidence could be as high as 4.22 million by 2028.

The Top Reasons to Consider Citius Pharmaceuticals (STOCK:CTXR)

 

 

 

Source 1: https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(20)30304-0/fulltext

Source 2: https://www.lung.org/lung-health-diseases/lung-disease-lookup/ards/ards-treatment-and-recovery

Source 3: https://www.biospace.com/article/releases/citius-signs-exclusive-option-with-novellus-to-license-novel-stem-cell-therapy-for-acute-respiratory-distress-syndrome-ards-associated-with-covid-19/

Source 4: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7301420/

Source 5: https://www.hopkinsmedicine.org/health/conditions-and-diseases/coronavirus/what-coronavirus-does-to-the-lungs

Source 6: https://www.prnewswire.com/news-releases/citius-receives-fda-response-on-pre-investigational-new-drug-pind-application-for-its-induced-mesenchymal-stem-cells-imscs-to-treat-acute-respiratory-distress-syndrome-ards-in-patients-with-covid-19-301084325.html

Source 7: https://www.sec.gov/Archives/edgar/data/1506251/000121390020008291/ea12027ex99-1_citiuspharm.htm

Source 8: https://www.prnewswire.com/news-releases/citius-pharmaceuticals-forms-scientific-advisory-board-for-the-planned-development-of-its-proprietary-treatment-for-acute-respiratory-disease-associated-with-covid-19-301098073.html

Source 9: https://www.prnewswire.com/news-releases/citius-pharmaceuticals-announces-improved-design-and-expansion-of-intellectual-property-for-mino-wrap-301118677.html

Source 10: https://www.citiuspharma.com/mino-lok/

Source 11: https://www.sec.gov/Archives/edgar/data/1506251/000121390020004698/f8k022520ex99-1_citiuspharma.htm

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

This website / media webpage is owned, operated and edited by TD Media  LLC.  Any wording found on this website / media webpage or disclaimer referencing to “I” or “we” or “our” or “TD Media” refers to TD Media LLC.  This website / media webpage is a paid advertisement, not a recommendation nor an offer to buy or sell securities. Our business model is to be financially compensated to market and promote small public companies.  By reading our website / media webpage you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature and are therefore are unqualified to give investment recommendations. Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis for making investment decisions and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. Companies with low price per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our website / media webpage.

We do not advise any reader take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website / media webpage are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our website / media webpage may be based on end-of-day or intraday data. This publication and their owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. If we own any shares we will list the information relevant to the stock and number of shares here. TD Media business model is to receive financial compensation to promote public companies. To conduct investor relations advertising, marketing and publicly disseminate information not limited to our Websites, Email, SMS, Push Notifications, Influencers, Social Media Postings, Ticker Tags, Press Releases, Online Interviews, Podcasts, Videos, Audio Ads, Banner Ads, Native Ads, Responsive Ads. This compensation is a major conflict of interest in our ability to be unbiased regarding. Therefore, this communication should be viewed as a commercial advertisement only.  We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices.  Any non-compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the investor relations marketing ceases. Our emails may contain forward-looking statements, which are not guaranteed to materialize due to a variety of factors

We do not guarantee the timeliness, accuracy, or completeness of the information on our website / media webpage. The information in our website / media webpage is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, TD Media often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice.

Pursuant to an agreement between TD Media LLC and Venado Media, TD Media LLC has been hired for a period beginning on 8/4/20 and ending on 8/10/20 to publicly disseminate information about (CTXR) via digital communications. We have been paid ten thousand USD via bank wire transfer. Pursuant to an agreement between TD Media LLC and Legends Media LLC, TD Media LLC has been hired for a period beginning on 8/17/20 and ending on 8/21/20 to publicly disseminate information about (CTXR) via digital communications. We have been paid and additional twenty thousand USD via bank wire transfer. Pursuant to an agreement between TD Media LLC and Legends Media LLC, TD Media LLC has been hired for a period beginning on 10/7/20 and ending on 10/8/20 to publicly disseminate information about (CTXR) via digital communications. We have been paid and additional seven thousand five hundred USD via bank wire transfer. We own zero shares of (CTXR). To date we have been paid thirty seven thousand five hundred USD via bank wire transfer to disseminate information about (CTXR) via digital communications.

Disclaimer

Privacy Policy